Clinical trials were missing from regulatory documents of extended-release methylphenidate for ADHD in adults: A case study of public documents.
2021
Objectives To assess whether drug regulatory agencies decided on applications for extended-release methylphenidate for use in adult ADHD based on select samples of trials. Study design and setting Case series of publicly available regulatory documents. We matched an index of extended-release methylphenidate trials for adult ADHD with trials appearing in regulatory documents of extended-release methylphenidate applications. Trials and regulatory documents were identified as part of this systematic review (https://doi.org/10.1002/14651858.CD012857). We sought to identify missing trials in the regulatory documents and to clarify regulatory submission requirements. Results We indexed 18 trials and matched those with 13 drug applications (11 approved, 2 rejected) published by 7 agencies. There were trials missing in 8 (62%) of 13 applications, median 3.5 trials (range 1-6). The median proportion of missing trial participants was 42% (range 14% - 72%). Regulators seemingly require that all trials must be included in new drug applications, but wording is ambiguous. Conclusion In this sample of extended-release methylphenidate drug applications for adult ADHD, 8 of 13 regulatory decisions were missing entire trials according to public documents, even though regulatory requirements seem to stipulate that all available trials should be included in drug applications.
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
23
References
0
Citations
NaN
KQI